To hear about similar clinical trials, please enter your email below
Trial Title:
Expanded Access to ABBV-400
NCT ID:
NCT05982873
Condition:
Non-Small Cell Lung Cancer
Conditions: Official terms:
Carcinoma, Non-Small-Cell Lung
Conditions: Keywords:
Expanded Access
Pre-approval Access
Compassionate Use
Special Access Program
Named Patient Basis
Special Access Scheme
Study type:
Expanded Access
Overall status:
Available
Intervention:
Intervention type:
Drug
Intervention name:
ABBV-400
Description:
Intravenous (IV) Infusion
Summary:
This is an expanded access program (EAP) for eligible participants. This program is
designed to provide access to ABBV-400 prior to approval by the local regulatory agency.
Availability will depend on territory eligibility. A medical doctor must decide whether
the potential benefit outweighs the risk of receiving an investigational therapy based on
the individual patient's medical history and program eligibility criteria.
Criteria for eligibility:
Criteria:
Inclusion Criteria:
- The participant must not be eligible for an ABBV-400 clinical trial.
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Lead sponsor:
Agency:
AbbVie
Agency class:
Industry
Source:
AbbVie
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05982873
https://www.abbvieclinicaltrials.com/study/?id=C24-738
